Aurinia Pharmaceuticals (AUPH) Free Cash Flow (2020 - 2026)

Aurinia Pharmaceuticals has reported Free Cash Flow for 7 years, with the latest figure at $32.5 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 2434.76% year-over-year to $32.5 million; the trailing twelve-month figure through Mar 2026 stood at $166.6 million (up 160.38% YoY), and the FY2025 full-year result was $135.4 million, up 206.99% from the prior year.
• Free Cash Flow for Q1 2026 stood at $32.5 million, down from $45.6 million in the prior quarter.
• The five-year high for Free Cash Flow was $45.6 million in Q4 2025, with the low at -$46.8 million in Q1 2022.
• Historically, Free Cash Flow has averaged $5.8 million across 5 years, with a median of $10.3 million in 2022.
• Annual changes were most pronounced in 2022 — Free Cash Flow grew 14.21% — and 2026, when it surged 2434.76%.
• Aurinia Pharmaceuticals' Free Cash Flow stood at $10.3 million in 2022, then jumped by 35.84% to $14.0 million in 2023, then jumped by 114.5% to $30.1 million in 2024, then surged by 51.69% to $45.6 million in 2025, then retreated by 28.68% to $32.5 million in 2026.
• The last three Free Cash Flow figures came in at $32.5 million (Q1 2026), $45.6 million (Q4 2025), and $44.4 million (Q3 2025), per Business Quant data.